Quick Takeaways
- PTHS - Pelthos Therapeutics Inc. has 17 insiders with reported activity on this page.
- Net insider value flow over the last year: -$337,400.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 17 Insiders of Pelthos Therapeutics Inc.
- Symbol
- PTHS on NYSE
- Location
- Durham, NC
What Changed
- Buy value: ; sell value: $337,400.
- Net share flow: <span class="text-red-600">-12,731</span>.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$337,400.
Buys
$0
Shares: 0
Insiders: 0
Sells
$337,400
Shares: 12,731
Insiders: 4
Net
-$337,400
Shares: -12,731
Insiders: -4
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 2,731 | $0 | $57,120 | +$57,120 |
| 3-6 | 0 | 10,000 | $0 | $280,280 | +$280,280 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Pelthos Therapeutics Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Todd C. Davis | Director | $16,264,921 | Mixed | 02 Jul 2025 | ||
| LIGAND PHARMACEUTICALS INC | Director, 10%+ Owner | $15,000,000 | Mixed | 17 Dec 2025 | ||
| Ezra M. Friedberg | Director | $4,931,416 | -$291,951 | -5.6% | Mixed | 02 Apr 2026 |
| Scott M. Plesha | CEO and President, Director | $2,117,890 | Market | 02 Jul 2025 | ||
| Francis Knuettel II | CFO, Treas & Secty | $1,424,648 | Market | 02 Jul 2025 | ||
| Sai Rangarao | Chief Commercial Officer | $772,410 | Market | 02 Jul 2025 | ||
| Richard Malamut | Director | $720,221 | -$12,340 | -1.7% | Mixed | 02 Apr 2026 |
| Peter Greenleaf | Director | $527,220 | -$16,670 | -3.1% | Filing P/S | 02 Apr 2026 |
| Richard B. Baxter | Director | $483,623 | Market | 02 Jul 2025 | ||
| Motif Pharmaceuticals Ltd. | 10%+ Owner | $442,434 | Mixed | 15 Feb 2024 | ||
| Boswell Prayer Ltd. | 10%+ Owner | $432,301 | Mixed | 15 Feb 2024 | ||
| Aperture Healthcare Ventures Ltd. | 10%+ Owner | $400,972 | Mixed | 15 Feb 2024 | ||
| Andrew J. Einhorn | Director | $342,000 | Mixed | 23 Dec 2025 | ||
| AME Equities LLC | 10%+ Owner | $330,093 | Mixed | 15 Feb 2024 | ||
| Matthew Pauls | Director | $323,646 | -$16,439 | -4.8% | Filing P/S | 02 Apr 2026 |
| Chia-Lin Simmons | Director | Mixed | 11 Apr 2025 | |||
| Eric Lang | Chief Medical Officer | Mixed | 14 Jun 2024 |
Top shareholders of Pelthos Therapeutics Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| LIGAND PHARMACEUTICALS INC |
13D/G
3/4/5
|
Ligand Pharmaceuticals Incorporated · Director, 10%+ Owner |
50%
|
5,189,177
|
$145,296,959 | +$7,316,652 | 06 Nov 2025 | |
| Todd C. Davis |
3/4/5
|
Director |
—
mixed-class rows
|
4,762,953
mixed-class rows
|
$16,264,921 | — | 02 Jul 2025 | |
| Murchinson Ltd. |
13F
13D/G
|
Company |
9.1%
from 13D/G
|
289,479
|
$8,973,849 | — | 31 Dec 2025 | |
| 3i, LP |
13D/G
|
— |
9.9%
|
318,886
|
$8,673,699 | +$428,346 | 31 Dec 2025 | |
| Ikarian Capital, LLC |
13F
13D/G
|
Company |
8.4%
from 13D/G
|
255,758
|
$7,928,498 | — | 31 Dec 2025 | |
| Ezra M. Friedberg |
3/4/5
13D/G
|
Director · Ezra Friedberg |
8.3%
from 13D/G
|
290,341
mixed-class rows
|
$4,931,416 | -$291,951 | 02 Apr 2026 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
2.6%
|
80,680
|
$2,501,080 | — | 31 Dec 2025 | |
| J. Goldman & Co LP |
13F
|
Company |
2.6%
|
78,006
|
$2,418,186 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.5%
|
75,020
|
$2,325,620 | — | 31 Dec 2025 | |
| Scott M. Plesha |
3/4/5
|
CEO and President, Director |
—
mixed-class rows
|
422,356
mixed-class rows
|
$2,117,890 | — | 02 Jul 2025 | |
| Francis Knuettel II |
3/4/5
|
CFO, Treas & Secty |
—
mixed-class rows
|
234,834
mixed-class rows
|
$1,424,648 | — | 02 Jul 2025 | |
| CANTOR FITZGERALD, L. P. |
13F
|
Individual |
1.1%
|
34,990
|
$1,084,690 | — | 31 Dec 2025 | |
| DIADEMA PARTNERS LP |
13F
|
Company |
0.82%
|
25,000
|
$775,000 | — | 31 Dec 2025 | |
| Sai Rangarao |
3/4/5
|
Chief Commercial Officer |
—
mixed-class rows
|
154,036
mixed-class rows
|
$772,410 | — | 02 Jul 2025 | |
| Alexandra Wood (Canada) Inc. |
13D/G
|
— |
9.5%
|
574,187
|
$734,959 | $0 | 13 Dec 2024 | |
| Richard Malamut |
3/4/5
|
Director |
—
mixed-class rows
|
114,704
mixed-class rows
|
$720,221 | -$12,340 | 02 Apr 2026 | |
| David M. Knott Jr. |
13F
|
Individual |
0.63%
|
19,281
|
$597,711 | — | 31 Dec 2025 | |
| Peter Greenleaf |
3/4/5
|
Director |
—
mixed-class rows
|
127,799
mixed-class rows
|
$527,220 | -$16,670 | 02 Apr 2026 | |
| Richard B. Baxter |
3/4/5
|
Director |
—
mixed-class rows
|
96,446
mixed-class rows
|
$483,623 | — | 02 Jul 2025 | |
| Motif Pharmaceuticals Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
470,674
|
$442,434 | — | 15 Feb 2024 | |
| Boswell Prayer Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
459,895
|
$432,301 | — | 15 Feb 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.45%
|
13,625
|
$422,375 | — | 31 Dec 2025 | |
| Aperture Healthcare Ventures Ltd. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
426,566
|
$400,972 | — | 15 Feb 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.36%
|
11,057
|
$342,767 | — | 31 Dec 2025 | |
| Andrew J. Einhorn |
3/4/5
|
Director |
0.39%
|
12,000
|
$342,000 | — | 23 Dec 2025 | |
| AME Equities LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
351,163
|
$330,093 | — | 15 Feb 2024 | |
| Matthew Pauls |
3/4/5
|
Director |
—
mixed-class rows
|
107,652
mixed-class rows
|
$323,646 | -$16,439 | 02 Apr 2026 | |
| Pale Fire Capital SE |
13F
|
Company |
0.27%
|
8,100
|
$251,100 | — | 31 Dec 2025 | |
| Persistent Asset Partners Ltd |
13F
|
Company |
0.2%
|
6,007
|
$186,217 | — | 31 Dec 2025 | |
| Steward Partners Investment Advisory, LLC |
13F
|
Company |
0.06%
|
1,910
|
$59,210 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
434
|
$13,454 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
12
|
$372 | — | 31 Dec 2025 | |
| Chia-Lin Simmons |
3/4/5
|
Director |
—
class O/S missing
|
235,000
|
— | — | 11 Apr 2025 | |
| Eric Lang |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
154,223
|
— | — | 14 Jun 2024 |
Recent Insider Transactions by Companies or Individuals for Pelthos Therapeutics Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Richard Malamut | PTHS | Common Stock | Sale | -2.11% | $12,340 | $20.92 | -590 | 27,422 | 02 Apr 2026 | Direct |
| Ezra M. Friedberg | PTHS | Common Stock | Sale | -0.68% | $11,671 | $20.92 | -558 | 82,027 | 02 Apr 2026 | Direct |
| Matthew Pauls | PTHS | Common Stock | Sale | -4.93% | $16,439 | $20.92 | -786 | 15,150 | 02 Apr 2026 | Direct |
| Peter Greenleaf | PTHS | Common Stock | Sale | -3.13% | $16,670 | $20.92 | -797 | 24,681 | 02 Apr 2026 | Direct |
| Andrew J. Einhorn | CHRO | Common Stock | Award | 12,000 | 12,000 | 23 Dec 2025 | Direct | |||
| Ligand Pharmaceuticals Inc | CHRO | Senior Secured Convertible Note | Award | 0 | $9,000,000 | 17 Dec 2025 | Direct | |||
| Ligand Pharmaceuticals Inc | CHRO | Senior Secured Convertible Note | Disposed to Issuer | 0 | 0 | 17 Dec 2025 | Direct | |||
| Matthew Pauls | CHRO | Common Stock | Gift | -89.9% | -9,542 | 1,074 | 10 Dec 2025 | Direct | ||
| Ezra M. Friedberg | CHRO | Common Stock | Sale | -25% | $280,280 | $28.03 | -10,000 | 30,000 | 25 Nov 2025 | By Balmoral Financial Group LLC |
| Richard Malamut | PTHS | Common Stock | Award | 38% | 2,454 | 8,904 | 13 Nov 2025 | Direct | ||
| Ligand Pharmaceuticals Inc | CHRO | Senior Secured Convertible Note | Award | 0 | $9,000,000 | 06 Nov 2025 | Direct | |||
| Matthew Pauls | CHRO | Common Stock | Options Exercise | 25% | 2,123 | 10,616 | 02 Oct 2025 | Direct | ||
| Matthew Pauls | CHRO | Restricted Stock Units | Options Exercise | -12.5% | -2,123 | 14,862 | 02 Oct 2025 | Direct | ||
| Ezra M. Friedberg | PTHS | Common Stock | Award | 30.1% | 19,108 | 82,585 | 02 Jul 2025 | Direct | ||
| Todd C. Davis | PTHS | Common Stock | Award | 92% | 19,108 | 39,886 | 02 Jul 2025 | Direct | ||
| Richard Malamut | PTHS | Common Stock | Award | 214.6% | 19,108 | 28,012 | 02 Jul 2025 | Direct | ||
| Scott M. Plesha | PTHS | Common Stock | Award | 83,678 | 83,678 | 02 Jul 2025 | Direct | |||
| Peter Greenleaf | PTHS | Common Stock | Award | 25,478 | 25,478 | 02 Jul 2025 | Direct | |||
| Matthew Pauls | PTHS | Common Stock | Award | 25,478 | 25,478 | 02 Jul 2025 | Direct | |||
| Sai Rangarao | PTHS | Common Stock | Award | 30,518 | 30,518 | 02 Jul 2025 | Direct | |||
| Richard B. Baxter | PTHS | Common Stock | Award | 19,108 | 19,108 | 02 Jul 2025 | Direct | |||
| Francis Knuettel II | PTHS | Common Stock | Award | 33,472 | 33,472 | 02 Jul 2025 | Direct | |||
| Matthew Pauls | CHRO | Common Stock | Options Exercise | 8,493 | 8,493 | 02 Jul 2025 | Direct | |||
| Matthew Pauls | CHRO | Restricted Stock Units | Options Exercise | -33.3% | -8,493 | 16,985 | 02 Jul 2025 | Direct | ||
| Todd C. Davis | CHRO | Stock Option | Award | 58,230 | 58,230 | 02 Jul 2025 | Direct | |||
| Todd C. Davis | CHRO | Restricted Stock Units | Award | 107% | 19,108 | 36,969 | 02 Jul 2025 | Direct | ||
| Ezra M. Friedberg | CHRO | Stock Option | Award | 58,230 | 58,230 | 02 Jul 2025 | Direct | |||
| Ezra M. Friedberg | CHRO | Restricted Stock Units | Award | 214.6% | 19,108 | 28,012 | 02 Jul 2025 | Direct | ||
| Richard Malamut | CHRO | Stock Option | Award | 58,230 | 58,230 | 02 Jul 2025 | Direct | |||
| Richard Malamut | CHRO | Restricted Stock Units | Award | 214.6% | 19,108 | 28,012 | 02 Jul 2025 | Direct | ||
| Ezra M. Friedberg | CHRO | Common Stock | Conversion of derivative security | 40,000 | 40,000 | 01 Jul 2025 | By Key Recovery Group LLC | |||
| Ezra M. Friedberg | CHRO | Common Stock | Conversion of derivative security | 40,000 | 40,000 | 01 Jul 2025 | By Balmoral Financial Group LLC | |||
| Ezra M. Friedberg | CHRO | Series A Convertible Preferred Stock | Conversion of derivative security | -100% | -40,000 | 0 | 01 Jul 2025 | By Key Recovery Group LLC | ||
| Ezra M. Friedberg | CHRO | Series A Convertible Preferred Stock | Conversion of derivative security | -100% | -40,000 | 0 | 01 Jul 2025 | By Balmoral Financial Group LLC | ||
| Ezra M. Friedberg | CHRO | Series A Convertible Preferred Stock | Purchase | 40,000 | 40,000 | 01 Jul 2025 | By Key Recovery Group LLC | |||
| Ezra M. Friedberg | CHRO | Series A Convertible Preferred Stock | Purchase | 40,000 | 40,000 | 01 Jul 2025 | By Balmoral Financial Group LLC | |||
| Francis Knuettel II | CHRO | Common Stock | Conversion of derivative security | 10,000 | 10,000 | 01 Jul 2025 | By Camden Capital LLC | |||
| Francis Knuettel II | CHRO | Series A Convertible Preferred Stock | Conversion of derivative security | -100% | -10,000 | 0 | 01 Jul 2025 | See footnote | ||
| Francis Knuettel II | CHRO | Series A Convertible Preferred Stock | Other | 10,000 | 10,000 | 01 Jul 2025 | See footnote | |||
| Todd C. Davis | CHRO | Common Stock | Conversion of derivative security | 1,500,000 | 1,500,000 | 01 Jul 2025 | By Ligand Pharmaceuticals Incorporated | |||
| Todd C. Davis | CHRO | Series A Convertible Preferred Stock | Other | 1.01% | 31,279 | 3,127,868 | 01 Jul 2025 | See footnote | ||
| Todd C. Davis | CHRO | Series A Convertible Preferred Stock | Conversion of derivative security | -83.3% | -15,000 | 3,000 | 01 Jul 2025 | See footnote | ||
| Ligand Pharmaceuticals Inc | CHRO | Common Stock | Conversion of derivative security | 1,500,000 | 1,500,000 | 01 Jul 2025 | Direct | |||
| Ligand Pharmaceuticals Inc | CHRO | Series A Convertible Preferred Stock | Other | 1042.6% | 31,279 | 34,279 | 01 Jul 2025 | Direct | ||
| Ligand Pharmaceuticals Inc | CHRO | Series A Convertible Preferred Stock | Conversion of derivative security | -83.3% | -15,000 | 3,000 | 01 Jul 2025 | Direct | ||
| Chia-Lin Simmons | CHRO | Stock Option | Award | 23.8% | 25,000 | 130,000 | 11 Apr 2025 | Direct | ||
| Francis Knuettel II | CHRO | Stock Option | Award | 14.3% | 53,988 | 430,736 | 11 Apr 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.